Armata Pharmaceuticals CEO Dr. Brian Varnum departs; severance includes 12-month salary continuation

Armata Pharmaceuticals, Inc.

Dr. Brian Varnum's employment terminated July 10, 2023; separation agreement signed July 14, 2023.
Severance includes base salary continuation for 12 months and COBRA premium payments for up to 12 months.
Unvested options that would have vested within one year will vest on first anniversary; exercise extended to Sept 30, 2024.
Agreement includes non-disparagement, confidentiality, and reaffirmation of existing restrictive covenants.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Dr. Brian Varnum

Chief Executive Officer

ARMP · Armata Pharmaceuticals, Inc.

Effective: 2023-07-10
Filed: July 19, 2023, 7:59 PM ET

On July 14, 2023, Armata Pharmaceuticals, Inc. (the “Company”) and Dr. Brian Varnum, the Company’s former Chief Executive Officer, entered into a separation and release agreement

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Brian Varnum resigned as Chief Executive Officer at Armata Pharmaceuticals, Inc..

Action: resigned
Role: Chief Executive Officer

Exact text from the filing

On July 14, 2023, Armata Pharmaceuticals, Inc. (the “Company”) and Dr. Brian Varnum, the Company’s former Chief Executive Officer, entered into a separation and release agreement

View on SEC.gov

Armata Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-082362

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.